empagliflozin, linagliptin, metformin hydrochloride

CHEBI:CHEBI_747064

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2359358
product_type
HUMAN PRESCRIPTION DRUG
marketing_category
NDA
listing_expiration_date
20251231
route
ORAL
active_ingredient_strength
2.5 mg/1
dosage_form
TABLET, EXTENDED RELEASE
active_ingredient_name
LINAGLIPTIN
unii
3X29ZEJ4R2
pharm_class
Dipeptidyl Peptidase 4 Inhibitors [MoA]
marketing_start_date
20200423
package_marketing_start_date
20200423
labeler_name
Boehringer Ingelheim Pharmaceuticals, Inc.
manufacturer_name
Boehringer Ingelheim Pharmaceuticals, Inc.
generic_name
empagliflozin, linagliptin, metformin hydrochloride
brand_name
Trijardy XR
brand_name_base
Trijardy XR
product_ndc
0597-0390
application_number
NDA212614
spl_id
706bd5df-de5d-476d-906e-13459e41f077
package_ndc
0597-0390-71
package_description
30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-71)
spl_set_id
71873567-9594-452a-bb92-34a129adecac
nui
N0000175913
pharm_class_epc
Dipeptidyl Peptidase 4 Inhibitor [EPC]
pharm_class_moa
Dipeptidyl Peptidase 4 Inhibitors [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class